The frontline indices marched higher and hit a fresh intraday high in mid-afternoon trade. The Nifty traded above the 17,800 mark after hitting day's low of 17,584.20 in mid-morning trade. Banks, financial services and consumer durables scrips were in demand while healthcare, pharma and realty stocks tumbled.
At 14:30 IST, the barometer index, the S&P BSE Sensex, was up 814.53 points or 1.36% to 60,746.77. The Nifty 50 index added 217.20 points or 1.23% to 17,827.60.
The broader market underperformed the headline indices. The S&P BSE Mid-Cap index lost 0.41% while the S&P BSE Small-Cap index fell 0.62%.
The market breadth was weak. On the BSE, 1,137 shares rose and 2,341 shares fell. A total of 140 shares were unchanged.
Numbers to Track:
The yield on India's 10-year benchmark federal paper fell to 7.290 from its close of 7.296 recorded in the previous trading session.
In the foreign exchange market, the rupee edged lower against the dollar. The partially convertible rupee was hovering at 82.2600, compared with its close of 82.2050 during the previous trading session.
MCX Gold futures for 3 February 2023 settlement rose 0.22% to Rs 57,820.
The United States 10-year bond yield fell 0.71% to 3.374.
In the commodities market, Brent crude for April 2023 settlement declined 35 cents or 0.43% to $81.82 a barrel.
Buzzing Index:
The Nifty PSU Bank index gained 2.14% to 3,853.30. The index slipped 5.84% in the past two trading sessions.
Bank of Baroda (up 5.03%), Canara Bank (up 1.84%), State Bank of India (up 1.78%), Bank of India (up 1.48%) and Indian Bank (up 0.1%) were the top gainers.
On the other hand, Central Bank of India (down 2.85%), UCO Bank (down 1.78%) and Union Bank of India (down 1.77%) edged lower.
Stocks in Spotlight:
Divis Laboratories tumbled 12.71% after the pharmaceutical company's consolidated net profit slumped 66% to Rs 306.80 crore on 31.51% decline in revenue from operations to Rs 1,707.68 crore in Q3 FY23 over Q3 FY22.
Mahanagar Gas (MGL) shed 0.08%. The company reported a consolidated net profit of Rs 172.07 crore in Q3 FY23, which is significantly higher as compared with a net profit of Rs 56.79 crore in Q3 FY22. Net revenue from operations increased by 62.62% YoY to Rs 1671.39 crore during the quarter.
Zydus Lifesciences rose 0.36%. The pharma company's consolidated net profit jumped 24.48% to Rs 622.9 crore on a 19.85% increase in total revenue from operations to Rs 4,362.3 crore in Q3 FY23 over Q3 FY22.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
Great minds don’t just skim the surface, they uncover the full story.
You’ve hit your limit of {{free_limit}} free articles this month, subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Months/month
Smart Essential
₹2700
1 Year
₹225/Months/month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories Online
Unlimited access to all articles
30+ premium stories daily, handpicked by our editor


Complimentary Access to The New York Times
News, Games, Cooking, Audio
Wirecutter & The Athletic
Complimentary Access to Our e-Paper
Digital replica of our daily newspaper
Read, save, share any article


Curated Newsletters on Diverse Topics
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Smart Investment Tips
In-depth stock analysis & insights
The Smart Investor for wealth growth tips


Access to Extensive Historical Archives
Repository of articles and publications dating back to 1997
Ad-free Reading Experience
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Repository of articles and publications dating back to 1997